Inceptua Group Selected to Manage TikoMed’s Named Patient Program for Investigational Therapy ILB® in Amyotrophic Lateral Sclerosis (ALS)

|

Windsor, London, UK, 26th August 2026.

Inceptua Group (Inceptua) and TikoMed AB (TikoMed) have announced the launch of a Named Patient Program for TikoMed’s investigational drug, ILB®, for eligible patients with Amyotrophic Lateral Sclerosis (ALS).

 

ALS, also known as Lou Gehrig’s disease, is a progressive, fatal neurodegenerative disorder. It progressively damages motor neurons in the brain and spinal cord, leading to severe muscle weakness, loss of voluntary movement, and eventually respiratory failure. ALS is a rare disease affecting about 2-3 in every 100,000 individuals worldwide. There is currently no cure for ALS.

 

A Named Patient Programme is a compliant way for medicines that are not approved in their country of intended use to be made available for patients who either have no alternative treatment option or have exhausted all other treatment options available in their country of residence. The ILB® Named Patient Program is designed to provide eligible patients with a pathway to access ILB® prior to regulatory approval, where permitted under local regulations.

“Inceptua is proud to support TikoMed in making its investigational product, ILB®, available whilst it is still going through the clinical trial development process. Patients with ALS have very limited treatment options.”
Stuart Bell
Executive Vice President, Inceptua Early Access
“TikoMed is happy to collaborate with Inceptua on this programme to help support access to ILB® for eligible patients with no alternative treatments for a life-threatening disease. Inceptua has a long and proven track record of providing Named Patient Programmes for the pharmaceutical industry and we are confident this collaboration will help provide an important access pathway for eligible patients across the globe.”
Björn Pilström
CEO and CMO of TikoMed

Requests for access to ILB® must be made by a Healthcare Professional (HCP). HCPs can request access for a patient by contacting Inceptua at: access@inceptua.com or calling + 44 20 3910 7670. 

About ILB® 

ILB® is an investigational drug that is currently being evaluated in a randomised Phase 2 clinical trial in patients with ALS. ILB® has shown encouraging preclinical findings in neurodegenerative conditions and has previously been evaluated in two small, uncontrolled clinical studies in patients with ALS. ILB® is an investigational medicinal product and has not been approved by any regulatory authority for the treatment of ALS.

About TikoMed

TikoMed is a privately held pharmaceutical company based in Sweden. TikoMed is developing innovative treatments for neurodegenerative diseases and other degenerative conditions through its drug candidate ILB®, a dextran sulfate that has shown a good safety profile and promising results for the treatment of ALS in limited phase 2a studies.

For more information, visit www.tikomed.com.

About Inceptua

Inceptua Early Access partners with pharma and biotech companies to provide truly global early access programs, which allow patients around the world access to potentially life-saving medicines. With offices in 8 countries, and a global warehousing and distribution network, Inceptua Early Access is the preferred partner for many companies in their efforts to bring promising medicines to patients as quickly as possible. Inceptua Early Access is a part of Inceptua Group – global service partner for pharma, delivering early access programs, clinical trial services, and distributes medicines worldwide.

For more information, visit www.inceptua.com and follow us on LinkedIn.

Inceptua Contact:
TikoMed Contact:
You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

CONTINUE